

Supporting Information (56 pages)

Photochemical conversion of isoxazoles to 5-hydroxyimidazolines

Taiki Morita,^{1,2} Shinichiro Fuse,^{1,2} Hiroyuki Nakamura*,^{1,2}

- 1) *School of Life Science and Engineering, Tokyo Institute of Technology, Yokohama, 226-8503, Japan*
2) *Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama, 226-8503, Japan*

Corresponding E-mail: hiro@res.titech.ac.jp

Table of Contents

1. General techniques	S2
2. Preparation of substrates	S2
3. General procedures for synthesis of 5-hydroxyimidazolines	S8
4. Dehydration of 5-hydroxyimidazolines	S16
5. References	S17
6. NMR spectra	S18


1. General Techniques

NMR spectra were recorded on a Bruker biospin AVANCE II (400 MHz for ¹H, 100 MHz for ¹³C) or a Bruker biospin AVANCE III (500 MHz for ¹H, 125 MHz for ¹³C) instrument in the indicated solvent. Chemical shifts are reported in units parts per million (ppm) relative to the signal (0.00 ppm) for internal tetramethylsilane for solutions in CDCl₃ (7.26 ppm for ¹H, 77.0 ppm for ¹³C) or DMSO-d₆ (2.50 ppm for ¹H) or CD₃OD (3.31 ppm for ¹H, 49.0 ppm for ¹³C). Multiplicities are reported using the following abbreviations: s; singlet, d; doublet, dd; doublet of doublets, t; triplet, q; quartet, m; multiplet, br; broad, J; coupling constants in Hertz. IR spectra were recorded on a JASCO FT/IR-4200 spectrometer. Only the strongest and/or structurally important peaks are reported as IR data given in cm⁻¹. ESI-TOF Mass spectra were measured using a Bruker micrOTOF II. HRMS (ESI-TOF) was calibrated as Leu-enkephalin or sodium formate. EI Mass spectra were measured using a JMS-700 Mstation. HRMS (EI, 70 eV) was calibrated as perfluorokerosene. All reactions were monitored by thin-layer chromatography carried out on 0.2 mm E. Merck silica gel plates (60F-254) with UV light (254 nm), and were visualized using an aqueous alkaline KMnO₄ solution. Gel permeation chromatography (GPC) for purification was performed on Japan Analytical Industry Model LC-9225 NEXT (recycling preparative HPLC) and a Japan Analytical Industry Model UV-600 NEXT ultra violet detector with a polystyrene gel column (JAIGEL-1H, 20 mm × 600 mm), using chloroform as solvent (3.5 mL/min). Column chromatography was performed on Silica Gel 60 N, purchased from Fuji Silysia Chemical Ltd. Preparative thin-layer chromatography (PTLC) was performed using Wakogel B5-F silica coated plates (1.0 mm) prepared in our laboratory. All the photochemical reactions were performed using a 6W UV lamp (wavelength: 254 nm), which was purchased from AS ONE Corporation (model: SLUV-6). A fluorinated ethylene propylene copolymer (FEP) tube was purchased from Flon Industry Co., Ltd (inner diameter: 1.0 mm).

2. Preparation of substrates


Representative procedure for synthesis of 3,5-bis{4-(trifluoromethyl)phenyl}isoxazole (**1f**)

To a mixture of *N*-hydroxy-4-(trifluoromethyl)benzimidoyl chloride¹ (894.3 mg, 4.00 mmol, 1.0 equiv.) and 1-ethynyl-4-(trifluoromethyl)benzene (714.5 mg, 4.20 mmol, 1.05 equiv.) in dichloromethane (12.0 mL), triethylamine (1.39 mL, 10.0 mmol, 2.5 equiv.) was added dropwise under an argon atmosphere at room temperature. After being stirred at 40 °C in an oil bath for 30 min, the reaction mixture was passed through a pad of silica gel and concentrated *in vacuo*. The residue was purified by silica gel column chromatography with hexane : ethyl acetate (97 : 3) to afford **1f** (496.0 mg, 1.39 mmol, 35%) as a white solid. Mp 129-132 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.00-7.95 (m, 4 H), 7.78-7.75 (m, 4H), 6.96 (s, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 169.4, 162.0, 132.2 (q, *J*_{C-F} = 32.9 Hz), 132.1, 132.1 (q, *J*_{C-F} = 32.9 Hz), 130.2, 127.2, 126.1, 126.0, 126.0, 123.8 (q, *J*_{C-F} = 272.2 Hz), 123.7 (q, *J*_{C-F} = 272.2 Hz), 98.9; FT-IR (neat): 1647, 1541, 1456, 1438, 1386, 1329, 1173, 1111, 1016, 951, 846 cm⁻¹; HRMS (ESI-TOF): calcd for [C₁₇H₉F₆NO +Na]⁺ 380.0481: found 380.0475.




3-(3,4-Dichlorophenyl)-5-{4-(trifluoromethyl)phenyl}isoxazole (1a**)**

Following the representative procedure using 3,4-dichloro-N-hydroxybenzimidoyl chloride, purification by PTLC with hexane : ethyl acetate (95 : 5) afforded **1a** (124 mg, 0.345 mmol, 82%) as a white solid. Mp 133-135 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.96-7.94 (m, 3H), 7.77 (d, *J* = 8.0 Hz, 2H), 7.71 (d, *J* = 8.5 Hz, 1H), 7.57 (d, *J* = 8.5 Hz, 1H), 6.90 (s, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 169.4, 161.3, 134.5, 133.4, 132.2 (q, *J*_{C-F} = 32.9 Hz), 131.1, 130.1, 128.7, 128.6, 126.2 (q, *J*_{C-F} = 5.6 Hz), 125.9, 123.6 (q, *J*_{C-F} = 272.3 Hz), 98.7; FT-IR (neat): 1646, 1602, 1492, 1444, 1325, 1169, 1068, 1031, 950, 891, 847 cm⁻¹; HRMS (EI, 70 eV): calcd. for [C₁₆H₈Cl₂F₃NO]⁺, 356.9935: found 356.9934.




5-{2-Chloro-4-(trifluoromethyl)phenyl}-3-(3,4-dichlorophenyl)isoxazole (1b**)**

Following the representative procedure using 3,4-dichloro-N-hydroxybenzimidoyl chloride, purification by silica gel column chromatography with hexane: ethyl acetate (97 : 3) afforded **1b** (217 mg, 0.554 mmol, 69%) as a white solid. Mp 122-124 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.14 (d, *J* = 8.2 Hz, 1H), 7.98 (d, *J* = 2.0 Hz, 1H), 7.80 (s, 1H), 7.73 (dd, *J* = 8.3, 2.0 Hz, 1H), 7.67 (d, *J* = 8.3, 1.1 Hz, 1H), 7.56 (d, *J* = 8.3 Hz, 1H), 7.32 (s, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 165.7, 161.2, 134.6, 133.4, 133.0 (q, *J*_{C-F} = 33.8 Hz), 132.2, 131.1, 129.8, 129.0, 128.7, 128.6, 128.0 (q, *J*_{C-F} = 3.9 Hz), 126.0, 124.2 (q, *J*_{C-F} = 3.5 Hz), 122.8 (q, *J*_{C-F} = 273.1 Hz), 103.3; FT-IR (neat): 1645, 1427, 1390, 1358, 1322, 1269, 1174, 1128, 1085, 1032, 886 cm⁻¹; HRMS (ESI-TOF): calcd for [C₁₆H₇Cl₃F₃NO + Na]⁺ 413.9438: found 413.9435.



3-(3,4-Dichlorophenyl)-5-(3,4-difluorophenyl)isoxazole (1c**)**


Following the representative procedure using 3,4-dichloro-N-hydroxybenzimidoyl chloride, purification by silica gel column chromatography with hexane: ethyl acetate (97 : 3) afforded **1c** (56.7 mg, 0.174 mmol, 22%) as a white solid. Mp 144-145 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.94 (s, 1H), 7.70-7.62 (m, 2H), 7.57-7.55 (m, 2H), 7.33-7.26 (m, 1H), 6.76 (s, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 168.8, 161.2, 151.6 (dd, *J*_{C-F} = 12.7, 254.1 Hz), 150.7 (dd, *J*_{C-F} = 13.2, 250.4 Hz), 134.4, 133.4, 131.1, 128.7, 128.6, 125.9, 124.1-124.0 (m), 122.5-122.4 (m), 118.3 (d, *J*_{C-F} = 18.0 Hz), 115.2 (d, *J*_{C-F} = 19.4 Hz), 97.8; FT-IR (neat): 1645, 1516, 1497, 1432, 1360, 1273, 1178, 878, 821 cm⁻¹; HRMS (ESI-TOF): calcd for [C₁₅H₇Cl₂F₂NO + Na]⁺ 347.9765: found 347.9768.



3-(3,4-Dichlorophenyl)-5-{4-fluoro-3-(trifluoromethyl)phenyl}isoxazole (1d**)**


Following the representative procedure using 3,4-dichloro-N-hydroxybenzimidoyl chloride, purification by silica gel column chromatography with hexane: ethyl acetate (97 : 3) afforded **1d** (106.4 mg, 0.283 mmol, 57%) as a white solid. Mp 100-101 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.05 (d, *J* = 6.3 Hz, 1H), 8.02-7.99 (m, 1H),

7.93 (d, $J = 1.4$ Hz, 1H), 7.68 (dd, $J = 8.3, 1.5$ Hz, 1H), 7.55 (d, $J = 8.3$ Hz, 1H), 7.35 (dd, $J = 9.1, 9.2$ Hz, 1H), 6.83 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 168.4, 161.3, 160.6 (dq, $J_{\text{C}-\text{F}} = 1.9, 261.7$ Hz), 134.5, 133.4, 131.3 (d, $J_{\text{C}-\text{F}} = 9.1$ Hz), 131.1, 128.6, 128.5, 125.9, 125.0 (dq, $J_{\text{C}-\text{F}} = 1.7, 4.2$ Hz), 123.7 (d, $J_{\text{C}-\text{F}} = 4.1$ Hz), 122.0 (q, $J_{\text{C}-\text{F}} = 272.5$ Hz), 119.5 (dq, $J_{\text{C}-\text{F}} = 13.4, 33.6$ Hz), 118.1 (dq, $J_{\text{C}-\text{F}} = 17.3, 4.3$ Hz), 98.0 (d, $J = 3.6$ Hz); FT-IR (neat): 1629, 1611, 1510, 1488, 1415, 1332, 1291, 1276, 1217, 1170, 1098, 1032, 968, 836 cm^{-1} ; HRMS (ESI-TOF): calcd for $[\text{C}_{16}\text{H}_7\text{Cl}_2\text{F}_4\text{NO} + \text{Na}]^+$ 397.9733: found 397.9728.




5-{3,5-Bis(trifluoromethyl)phenyl}-3-(3,4-dichlorophenyl)isoxazole (1e)

Following the representative procedure using 3,4-dichloro-*N*-hydroxybenzimidoyl chloride, purification by silica gel column chromatography with hexane: ethyl acetate (97 : 3) afforded **1e** (76.2 mg, 0.179 mmol, 26%) as a white solid. Mp 129–132 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.24 (s, 2 H), 7.97–7.92 (m, 2H), 7.68 (d, $J = 7.8$ Hz, 1H), 7.56–7.53 (m, 1H), 6.99 (s, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 167.7, 161.5, 134.8, 133.5, 132.9 (q, $J_{\text{C}-\text{F}} = 33.9$ Hz), 131.1, 128.9, 128.7, 128.2, 125.9, 125.8 (q, $J_{\text{C}-\text{F}} = 3.5$ Hz), 123.9–123.7 (m), 122.8 (q, $J_{\text{C}-\text{F}} = 272.8$ Hz), 99.4; FT-IR (neat): 1634, 1557, 1456, 1416, 1371, 1357, 1279, 1188, 1093, 1034, 980, 845 cm^{-1} ; HRMS (ESI-TOF): calcd for $[\text{C}_{17}\text{H}_7\text{Cl}_2\text{F}_6\text{NO} + \text{Na}]^+$ 447.9701: found 447.9706.



3-(4-Chlorophenyl)-5-{4-(trifluoromethyl)phenyl}isoxazole (1g)


Following the representative procedure using 4-chloro-*N*-hydroxybenzimidoyl chloride, purification by silica gel column chromatography with hexane: ethyl acetate (97 : 3) afforded **1g** (141.9 mg, 0.438 mmol, 44%) as a white solid. Mp 129–132 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.94 (d, $J = 8.2$ Hz, 2H), 7.81–7.79 (m, 2H), 7.75 (d, $J = 8.2$ Hz, 2H), 7.48–7.44 (m, 2H), 6.90 (s, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 169.0, 162.2, 136.3, 132.0 (q, $J_{\text{C}-\text{F}} = 32.9$ Hz), 130.3, 129.3, 128.1, 127.2, 126.1, 126.1 (q, $J_{\text{C}-\text{F}} = 3.6$ Hz), 123.7 (q, $J_{\text{C}-\text{F}} = 272.5$ Hz), 98.7; FT-IR (neat): 1641, 1603, 1549, 1494, 1468, 1413, 1265, 1175, 1098, 1066, 950, 848 cm^{-1} ; HRMS (ESI-TOF): calcd for $[\text{C}_{16}\text{H}_9\text{ClF}_3\text{NO} + \text{Na}]^+$ 346.0217: found 346.0216.



3-(4-Fluorophenyl)-5-{4-(trifluoromethyl)phenyl}isoxazole (1h)


Following the representative procedure using 4-fluoro-*N*-hydroxybenzimidoyl chloride, purification by silica gel column chromatography with hexane: ethyl acetate (97 : 3) afforded **1h** (170.3 mg, 0.554 mmol, 69%) as a white solid. Mp 129–132 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.94 (d, $J = 8.2$ Hz, 2H), 7.87–7.83 (m, 2H), 7.75 (d, $J = 8.2$ Hz, 2H), 7.18 (dd, $J = 8.6, 8.6$ Hz, 2H), 6.88 (s, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 168.9, 163.9 (d,

$J_{C-F} = 250.3$ Hz), 162.2, 131.9 (q, $J_{C-F} = 32.8$ Hz), 130.4, 128.7 (d, $J_{C-F} = 8.5$ Hz), 126.1 (q, $J_{C-F} = 3.6$ Hz), 126.1, 124.9 (d, $J_{C-F} = 3.3$ Hz), 123.7 (q, $J_{C-F} = 272.5$ Hz), 116.1 (d, $J_{C-F} = 21.9$ Hz), 98.7; FT-IR (neat): 1607, 1511, 1435, 1413, 1333, 1173, 1112, 1087, 1070, 951, 845 cm⁻¹; HRMS (ESI-TOF): calcd for [C₁₆H₉F₄NO +Na]⁺ 330.0512: found 330.0507.




3-(2-Fluorophenyl)-5-{4-(trifluoromethyl)phenyl}isoxazole (1i)

Following the representative procedure using 2-fluoro-N-hydroxybenzimidoyl chloride, purification by silica gel column chromatography with hexane: ethyl acetate (97 : 3) afforded **1i** (118.9 mg, 0.387 mmol, 39%) as a white solid. Mp 129-132 °C. ¹H NMR (500 MHz, CDCl₃) δ 8.05 (t, $J = 7.3, 7.4$ Hz, 1H), 7.96 (d, $J = 8.1$ Hz, 2H), 7.75 (d, $J = 8.1$ Hz, 2H), 7.48-7.44 (m, 1H), 7.29-7.26 (m, 1H), 7.23-7.19 (m, 1H), 7.08 (d, $J = 3.2$ Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 168.6, 160.3 (d, $J_{C-F} = 251.6$ Hz), 131.9 (d, $J_{C-F} = 8.6$ Hz), 131.9 (q, $J_{C-F} = 32.7$ Hz), 130.5, 129.1 (d, $J_{C-F} = 2.6$ Hz), 126.1, 126.1 (q, $J_{C-F} = 3.9$ Hz), 124.7 (d, $J_{C-F} = 3.4$ Hz), 123.7 (q, $J_{C-F} = 272.4$ Hz), 116.8 (d, $J_{C-F} = 21.9$ Hz), 116.4 (d, $J_{C-F} = 21.9$ Hz), 101.5 (d, $J_{C-F} = 9.3$ Hz); FT-IR (neat): 1620, 1581, 1502, 1469, 1432, 1327, 1221, 1168, 1112, 1067, 951, 845 cm⁻¹; HRMS (ESI-TOF): calcd for [C₁₆H₉F₄NO +Na]⁺ 330.0512: found 330.0509.



3-{4-Chloro-3-(trifluoromethyl)phenyl}-5-{4-(trifluoromethyl)phenyl}isoxazole (1j)


Following the representative procedure using 4-fluoro-N-hydroxy-3-(trifluoromethyl)benzimidoyl chloride, purification by silica gel column chromatography with hexane: ethyl acetate (97 : 3) afforded **1j** (166.4 mg, 0.443 mmol, 55%) as a white solid. Mp 114-116 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.11-8.06 (m, 2H), 7.96 (d, $J = 8.2$ Hz, 2H), 7.77 (d, $J = 8.2$ Hz, 2H), 7.34 (dd, $J = 9.2, 9.2$ Hz, 1H), 6.93 (s, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 169.6, 161.2, 160.7 (dq, $J = 2.0, 260.8$ Hz), 132.3 (q, $J_{C-F} = 32.8$ Hz), 132.2 (d, $J_{C-F} = 8.9$ Hz), 130.1, 126.2 (q, $J_{C-F} = 3.7$ Hz), 126.2, 125.9-125.8 (m), 125.4 (q, $J_{C-F} = 3.8$ Hz), 123.6 (q, $J_{C-F} = 272.5$ Hz), 122.2 (d, $J_{C-F} = 272.7$ Hz), 119.5-119.1 (m), 117.9 (d, $J_{C-F} = 21.2$ Hz), 98.6; FT-IR (neat): 1627, 1606, 1505, 1415, 1379, 1327, 1242, 1157, 1097, 1057, 1020, 951, 850 cm⁻¹; HRMS (EI, 70 eV): calcd. for [C₁₇H₈F₇NO]⁺, 375.0494: found 375.0494.



3-(4-Fluoro-3-methoxyphenyl)-5-{4-(trifluoromethyl)phenyl}isoxazole (1k)


Following the representative procedure using 4-fluoro-N-hydroxy-3-methoxybenzimidoyl chloride, purification by silica gel column chromatography with hexane: ethyl acetate (97 : 3) afforded **1k** (222.5mg,

0.660 mmol, 82%) as a white solid. Mp 121-123 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.90 (d, $J = 8.2$ Hz, 2H), 7.40 (d, $J = 8.2$ Hz, 2H), 7.52 (dd, $J = 1.6, 8.1$ Hz, 1H), 7.31-7.27 (m, 1H), 7.16-7.11 (m, 1H), 6.85 (s, 1H), 3.94 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 168.8, 162.3, 153.6 (d, $J_{\text{C}-\text{F}} = 250.6$ Hz), 148.1 (d, $J_{\text{C}-\text{F}} = 11.1$ Hz), 131.9 (q, $J_{\text{C}-\text{F}} = 32.8$ Hz), 130.3, 126.0, 125.1 (d, $J_{\text{C}-\text{F}} = 3.9$ Hz), 123.6 (q, $J_{\text{C}-\text{F}} = 272.2$ Hz), 119.7 (d, $J_{\text{C}-\text{F}} = 7.4$ Hz), 116.4 (d, $J_{\text{C}-\text{F}} = 19.2$ Hz), 111.4 (d, $J_{\text{C}-\text{F}} = 3.0$ Hz), 98.7 (d, $J_{\text{C}-\text{F}} = 3.7$ Hz), 56.2; FT-IR (neat): 2979, 1606, 1584, 1574, 1510, 1412, 1370, 1220, 1136, 1035, 1013, 948, 931, 838 cm^{-1} ; HRMS (ESI-TOF): calcd for $[\text{C}_{17}\text{H}_{11}\text{F}_4\text{NO}_2 + \text{Na}]^+$ 360.0618: found 360.0614.



3-(4-Fluoro-2-methylphenyl)-5-{4-(trifluoromethyl)phenyl}isoxazole (1l)

Following the representative procedure using 4-fluoro-N-hydroxy-2-methylbenzimidoyl chloride, purification by silica gel column chromatography with hexane: ethyl acetate (97 : 3) afforded **1l** (180.5mg, 0.562 mmol, 70%) as a white solid. Mp 71-72 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.93 (d, $J = 7.9$ Hz, 2H), 7.73 (d, $J = 7.9$ Hz, 2H), 7.54-7.50 (m, 1H), 7.03-6.96 (m, 2H), 2.51 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 168.0, 163.3 (d, $J_{\text{C}-\text{F}} = 249.4$ Hz), 162.0, 139.7 (d, $J_{\text{C}-\text{F}} = 8.2$ Hz), 131.9 (q, $J_{\text{C}-\text{F}} = 32.7$ Hz), 131.2 (d, $J_{\text{C}-\text{F}} = 8.8$ Hz), 130.4, 126.0, 126.0 (q, $J_{\text{C}-\text{F}} = 3.8$ Hz), 124.5 (d, $J_{\text{C}-\text{F}} = 2.9$ Hz), 123.7 (q, $J_{\text{C}-\text{F}} = 272.3$ Hz), 117.8 (d, $J_{\text{C}-\text{F}} = 21.4$ Hz), 113.1 (d, $J_{\text{C}-\text{F}} = 21.5$ Hz), 101.4; FT-IR (neat): 2924, 1613, 1587, 1505, 1446, 1416, 1284, 1234, 1191, 1158, 1011, 967, 874, 845 cm^{-1} ; HRMS (ESI-TOF): calcd for $[\text{C}_{17}\text{H}_{11}\text{F}_4\text{NO} + \text{Na}]^+$ 344.0669: found 344.0669.




3-(4-Chlorophenyl)-5-phenylisoxazol-4-ol

To a stirred solution of 3-(4-chlorophenyl)-4-iodo-5-phenylisoxazole²⁾ (131.3 mg, 0.344 mmol, 1.0 equiv.) in THF (3.44 mL), $^i\text{PrMgCl} \cdot \text{LiCl}$ in THF (0.82 M, 0.504 mL, 1.2 equiv.) was added dropwise at -78 °C under an argon atmosphere. After being stirred at the same temperature for 30 min, 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborane (84 μL , 0.413 mmol, 1.2 equiv.) was added. After being stirred at 0 °C for 1 h, the reaction mixture was poured into water with ethyl acetate, then acidified with 1 M aq. HCl. The aqueous layer was extracted with two portions of ethyl acetate. The combined extract was dried over Na_2SO_4 and concentrated *in vacuo*. The residue was dissolved in THF (1.1 mL), then H_2O (980 μL), NaOH (41.3 mg, 1.03 mmol, 3.0 equiv.) and 30% H_2O_2 (117 μL , 1.03 mmol, 3.0 equiv.) were added to the solution at 0 °C under an argon atmosphere. After being stirred at 0 °C for 30 min, the reaction mixture was poured into ethyl acetate. The aqueous layer was extracted with two portions of ethyl acetate. The combined extract was washed with brine, dried over MgSO_4 and concentrated. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 70 : 20) to give 3-(4-chlorophenyl)-5-phenylisoxazol-4-ol (55.9 mg, 0.206 mmol, 60 %) as a white solid.

Mp 147-149 °C. ^1H NMR (400 MHz, CD_3OD) δ 8.00-7.96 (m, 4H), 7.54-7.48 (m, 4H), 7.43-7.39 (m, 1H); ^{13}C


NMR (125 MHz, CD₃OD) δ 157.2, 156.7, 137.4, 134.7, 130.7, 130.6, 130.5, 130.4, 129.6, 129.1, 126.6; FT-IR (neat): 3026, 2925, 1631, 1599, 1444, 1392, 1306, 1270, 1208, 1146, 1049, 945, 919, 838 cm⁻¹; HRMS (ESI-TOF): calcd for [C₁₅H₁₀ClNO₂ -H]⁻ 270.0327: found 270.0332.



3-(4-Chlorophenyl)-4-methoxy-5-phenyloxazole (1m)

To a stirred solution of 3-(4-chlorophenyl)-5-phenyloxazol-4-ol (252.0 mg, 0.927 mmol, 1.0 equiv.) in DMF (1.86 mL), Cs₂CO₃ (393.9 mg, 1.21 mmol, 1.3 equiv.) and methyl iodide (115.5 μL, 1.85 mmol, 2.0 equiv.) were added at room temperature. After being stirred at 50 °C in an oil bath for 30 min, the reaction mixture was poured into water. The aqueous layer was extracted with two portions of diethyl ether. The combined extract was washed with brine, dried over MgSO₄ and concentrated in vacuo. The residue was purified by PTLC with hexane : ethyl acetate = 90 : 10 to give 3-(4-chlorophenyl)-4-methoxy-5-phenyloxazole (**1m**) (187.5 mg, 0.656 mmol, 71%).


Colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.97-7.94 (m, 4H), 7.53-7.44 (m, 5H), 3.73 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 157.7, 155.9, 137.0, 136.1, 129.8, 129.2, 129.0, 128.4, 127.0, 126.7, 125.4, 61.6; FT-IR (neat): 2935, 1658, 1601, 1549, 1461, 1445, 1423, 1386, 1308, 1215, 1051, 1015, 985, 836 cm⁻¹; HRMS (ESI-TOF): calcd for [C₁₆H₁₂ClNO₂ +Na]⁺ 308.0449: found 308.0443.



3-(4-Chlorophenyl)-4-methoxyisoxazole (1n)

To a stirred solution of 3-(4-chlorophenyl)-isoxazol-4-ol³⁾ (101.3 mg, 0.518 mmol, 1.0 equiv.) in DMF (1.0 mL), Cs₂CO₃ (253.1 mg, 0.777 mmol, 1.5 equiv.) and methyl iodide (65 μL, 1.04 mmol, 2.0 equiv.) was added at room temperature. After being stirred at 50 °C in an oil bath for 30 min, the reaction mixture was poured into water. The aqueous layer was extracted with two portions of diethyl ether. The combined extract was washed with brine, dried over MgSO₄ and concentrated in vacuo. The residue was purified by column chromatography on silica gel with hexane : ethyl acetate = 90 : 10 to give 3-(4-chlorophenyl)-4-methoxyisoxazole (**1n**) (78.3 mg, 0.274 mmol, 53%) as a white solid.


Mp 63-65 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.15 (s, 1H), 7.93 (d, *J* = 8.4 Hz, 2H), 7.42 (d, *J* = 8.4 Hz, 2H), 3.87 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 152.0, 143.3, 139.6, 135.8, 128.9, 128.5, 126.5, 59.6; FT-IR (neat): 3104, 2834, 1570, 1514, 1466, 1377, 1288, 1258, 1110, 1002, 918, 898, 829 cm⁻¹; HRMS (ESI-TOF): calcd for [C₁₀H₈ClNO₂ +H]⁺ 210.0316: found 210.0309.



4-((6-Azidohexyl)oxy)-3-(4-chlorophenyl)isoxazole (1o**)**

To a stirred solution of 3-(4-chlorophenyl) isoxazol-4-ol (20.3 mg, 0.104 mmol, 1.0 equiv.) in DMF (0.600 mL), Cs₂CO₃ (44.0 mg, 0.135 mmol, 1.3 equiv.) and 1-azide-6-bromohexane (27.8 mg, 0.135 mmol, 1.3 equiv.) were added at room temperature. After being stirred at 50 °C in an oil bath for 30 min, the reaction mixture was poured into water. The aqueous layer was extracted with two portions of diethyl ether. The combined extract was washed with brine, dried over MgSO₄ and concentrated in vacuo. The residue was purified by column chromatography on silica gel with hexane : ethyl acetate = 90 : 10 to give 4-((6-azidohexyl)oxy)-3-(4-chlorophenyl)isoxazole (**1o**) (32.0 mg, 0.0998 mmol, 96%).

Colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 8.14 (s, 1H), 7.94 (d, *J* = 8.5 Hz, 2H), 7.43 (d, *J* = 8.5 Hz, 2H), 3.95 (t, *J* = 6.4, 2H), 3.28 (t, *J* = 6.8, 2H), 1.85 (sext, *J* = 6.8 Hz, 2H), 1.63 (sext, *J* = 7.0 Hz, 2H), 1.51-1.46 (m, 4H); ¹³C NMR (125 MHz, CD₃Cl) δ 152.1, 142.1, 140.0, 135.7, 128.9, 128.5, 126.6, 72.6, 51.3, 29.0, 28.7, 26.4, 25.6; FT-IR (neat): 2941, 2863, 2094, 1615, 1514, 1456, 1427, 1255, 1092, 1048, 1015, 921, 895, 836 cm⁻¹; HRMS (ESI-TOF): calcd for [C₁₅H₁₇ClN₄O₂ + Na]⁺ 343.0932: found 343.0926.



3. Photochemical conversion of isoxazoles **1 to 5-hydroxyimidazolines **2****

Representative procedure for the synthesis of 2-(3,4-Dichlorophenyl)-1-propyl-5-{4-(trifluoromethyl)phenyl}-4,5-dihydro-1*H*-imidazol-5-ol (2a**).**

A solution of 3-(3,4-dichlorophenyl)-5-{4-(trifluoromethyl)phenyl}isoxazole (**1a**) (358.1 mg, 1.00 mmol, 1.0 equiv.) in propylamine (10.0 mL) and H₂O (2.00 mL) was introduced into the tube reactor (FEP tube, inner diameter: 1.0 mm) at room temperature, and the mixture was irradiated with a 6 W UV lamp (Figure S1). After 30 min, the reaction mixture was collected by washing the tube with dichloromethane and methanol, and concentrated in vacuo. The residue was purified by PTLC (dichloromethane: methanol = 77 : 3) to give corresponding imidazoline 2-(3,4-dichlorophenyl)-1-propyl-5-{4-(trifluoromethyl)phenyl}-4,5-dihydro-1*H*-imidazol-5-ol (**2a**) (274.1 mg, 0.657 mmol, 66% yield). When the reaction was carried out at 0.1 mmol scale (**1a**; 35.8 mg, 0.1 mmol), **2a** was obtained in 73% yield (25.4 mg, 0.0609 mmol) and this result is indicated in Table 1, entry 2. Purification of other compounds **2** was also carried out by PTLC using dichloromethane/methanol (77 : 3) except where indicated.

Decomposition Temperature: 151-153 °C. ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.84-7.73 (m, 6H), 7.59 (d, *J* = 7.9 Hz, 1H), 6.79 (brs, 1H), 3.94 (d, *J* = 16.4 Hz, 1H), 3.81 (d, *J* = 16.4 Hz, 1H), 3.13-3.07 (m, 1H), 2.74-2.68 (m, 1H), 1.27-1.17 (m, 1H), 1.00-0.92 (m, 1H), 0.51 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃/CD₃OD (20 : 1)) δ 163.1, 146.7, 134.3, 132.9, 131.4, 130.6, 130.1, 129.9, 127.0, 126.6, 125.0 (q, *J*_{C-F} = 3.7 Hz), 124.0 (q, *J*_{C-F} = 272.0 Hz), 94.4, 69.5, 44.2, 23.9, 11.2; ¹⁹F NMR (376 MHz, CDCl₃) δ -60.8; FT-IR (neat): 3069, 2964, 2932, 1619, 1580, 1455, 1410, 1329, 1295, 1238, 1159, 1125, 1105, 1087, 1067, 1014, 982, 931, 847; HRMS (ESI-TOF): calcd for [C₁₉H₁₇Cl₂F₃N₂O + H]⁺ 417.0743: found 417.0737.






Figure S1. The reactor for photochemical reaction


2-(3,4-Dichlorophenyl)-1-butyl-5-{4-(trifluoromethyl)phenyl}-4,5-dihydro-1*H*-imidazol-5-ol (**2b**)

Following the representative procedure, **2b** was obtained (40.6 mg, 0.0941 mmol, 69%) as a white solid from **1a** (48.7 mg, 0.136 mmol). Decomposition Temperature: 168-171 °C. ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.84-7.73 (m, 6H), 7.59 (dd, *J*=8.3, 1.9 Hz, 1H), 6.78 (brs, 1H), 3.94 (d, *J*=16.4 Hz, 1H), 3.82 (d, *J*=16.4 Hz, 1H), 3.16-3.10 (m, 1H), 2.78-2.72 (m, 1H), 1.22-1.16 (m, 1H), 0.97-0.89 (m, 3H), 0.54 (t, *J*=7.1 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃/CD₃OD (20 : 1)) δ 163.1, 146.7, 134.3, 132.8, 131.4, 130.6, 130.0 (q, *J*_{C-F}=32.7 Hz), 129.8, 127.0, 126.6, 125.0 (q, *J*_{C-F}=3.7 Hz), 123.9 (q, *J*_{C-F}=272.1 Hz), 94.4, 69.6, 42.0, 32.5, 19.8, 13.1; FT-IR (neat): 2957, 2936, 1648, 1558, 1541, 1489, 1457, 1327, 1236, 1067, 1015, 944, 824; HRMS (ESI-TOF): calcd for [C₂₀H₁₉Cl₂F₃N₂O +H]⁺ 431.0899; found 431.0903.




5-{2-Chloro-4-(trifluoromethyl)phenyl}-2-(3,4-dichlorophenyl)-1-propyl-4,5-dihydro-1*H*-imidazol-5-ol (**2c**)

Following the representative procedure, **2c** was obtained (29.2 mg, 0.0646 mmol, 65%) as a white solid from **1b**. Decomposition temperature: 142-144 °C. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.17 (d, *J*=8.3 Hz, 1H), 7.86 (s, 1H), 7.74 (d, *J*=8.3 Hz, 2H), 7.72 (d, *J*=1.4 Hz, 1H), 7.52 (dd, *J*=1.4, 8.3, Hz, 1H), 7.02 (brs, 1H), 4.06 (d, *J*=16.7 Hz, 1H), 3.86 (d, *J*=16.7 Hz, 1H), 3.11-3.05 (m, 1H), 2.68-2.62 (m, 1H), 1.28-1.22 (m, 1H), 1.03-0.92 (m, 1H), 0.51 (t, *J*=7.4 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 162.5, 143.0, 134.6, 133.2, 133.0, 131.7 (q, *J*_{C-F}=33.1 Hz), 131.1, 130.5, 130.3, 130.2, 128.0 (q, *J*_{C-F}=3.7 Hz), 127.1, 123.4 (q, *J*_{C-F}=3.4 Hz), 123.4 (q, *J*_{C-F}=272.6 Hz), 92.5, 66.4, 44.3, 23.6, 11.3; FT-IR (neat): 3063, 2967, 2932, 1608, 1582, 1484, 1419, 1393, 1326, 1259, 1232, 1172, 1133, 1081, 977, 890, 841; HRMS (ESI-TOF): calcd for [C₁₉H₁₆C₃F₃N₂O +H]⁺ 451.0353; found 451.0358.




2-(3,4-Dichlorophenyl)-5-(3,4-difluorophenyl)-1-propyl-4,5-dihydro-1*H*-imidazol-5-ol (2d)

Following the representative procedure, **2d** was obtained (34.4 mg, 0.0893 mmol, 53%) as a white solid from **1c** (55.0 mg, 0.169 mmol). Decomposition temperature: 143–145 °C. ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.85 (d, *J* = 1.7 Hz, 1H), 7.76 (d, *J* = 8.3 Hz), 7.60–7.53 (m, 2H), 7.45–7.40 (m, 2H), 6.75 (brs, 1H), 3.90 (d, *J* = 16.3 Hz, 1H), 3.79 (d, *J* = 16.3 Hz, 1H), 3.11–3.05 (m, 1H), 2.73–2.67 (m, 1H), 1.27–1.20 (m, 1H), 1.00–0.92 (m, 1H), 0.51 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃/CD₃OD (25 : 1)) δ 162.8, 149.9 (d, *J*_{C-F} = 248.2 Hz), 149.8 (d, *J*_{C-F} = 248.2 Hz), 139.9, 134.4, 132.9, 131.5, 130.6, 129.9, 127.0, 122.5, 116.8 (d, *J*_{C-F} = 17.3 Hz), 115.7 (d, *J*_{C-F} = 18.5 Hz), 93.9, 69.0, 44.2, 23.9, 11.3; FT-IR (neat): 3413, 2967, 2935, 1610, 1583, 1518, 1417, 1376, 1282, 1196, 1110, 1033, 984, 886, 825 cm⁻¹; HRMS (ESI-TOF): calcd for [C₁₈H₁₆Cl₂F₂N₂O + H]⁺ 385.0681; found 385.0678.



2-(3,4-Dichlorophenyl)-5-{4-fluoro-3-(trifluoromethyl)phenyl}-1-propyl-4,5-dihydro-1*H*-imidazol-5-ol (2e)


Following the representative procedure, **2e** was obtained (29.1 mg, 0.0669 mmol, 67%) as a white solid from **1d** (37.6 mg, 0.100 mmol). Decomposition temperature: 144–146 °C. ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.93–7.84 (m, 3H), 7.78 (d, *J* = 8.3 Hz, 1H), 7.59 (dd, *J* = 1.8, 8.2 Hz, 1H), 7.54–7.50 (m, 1H), 6.89 (brs, 1H), 3.93 (d, *J* = 16.4 Hz, 1H), 3.82 (d, *J* = 16.4 Hz, 1H), 3.12–3.06 (m, 1H), 2.74–2.68 (m, 1H), 1.24–1.16 (m, 1H), 0.97–0.90 (m, 1H), 0.51 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃/CD₃OD (20 : 1)) δ 163.1, 159.3 (d, *J*_{C-F} = 257.5 Hz), 139.2, 134.5, 132.9, 132.0 (d, *J*_{C-F} = 8.2 Hz), 131.4, 130.6, 129.9, 127.0, 125.3, 122.5 (q, *J*_{C-F} = 272.2 Hz), 117.9 (dq, *J*_{C-F} = 12.3, 33.4 Hz), 116.6 (d, *J*_{C-F} = 20.8 Hz), 94.0, 69.4, 44.1, 23.9, 11.2; FT-IR (neat): 3093, 2968, 1622, 1604, 1583, 1505, 1419, 1323, 1243, 1135, 1082, 1034, 982, 892, 830 cm⁻¹; HRMS (ESI-TOF): calcd for [C₁₉H₁₆Cl₂F₄N₂O + H]⁺ 435.0649; found 435.0646.



5-{3,5-bis(trifluoromethyl)phenyl}-2-(3,4-dichlorophenyl)-1-propyl-4,5-dihydro-1*H*-imidazol-5-ol (2f)


Following the representative procedure, afforded **2f** (20.6 mg, 0.0425 mmol, 54%) as a white solid from **1e** (33.6 mg, 0.0788 mmol). Decomposition temperature: 156–158 °C. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.19 (s, 2H), 8.09 (s, 1H), 7.88 (d, *J* = 1.7 Hz, 1H), 7.78 (d, *J* = 8.3 Hz, 1H), 7.63 (dd, *J* = 1.7, 8.3 Hz, 1H), 7.13 (brs, 1H), 3.97 (d, *J* = 16.5 Hz, 1H), 3.87 (d, *J* = 16.5 Hz, 1H), 3.14–3.08 (m, 1H), 2.75–2.69 (m, 1H), 1.19–1.12 (m,

1H), 0.94-0.86 (m, 1H), 0.50 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (125 MHz, $\text{CDCl}_3/\text{CD}_3\text{OD}$ (20 : 1)) δ 163.5, 146.0, 134.4, 132.8, 131.4 (q, $J_{\text{C}-\text{F}} = 33.5$ Hz), 131.1, 130.6, 129.8, 127.0, 126.5, 123.1 (q, $J_{\text{C}-\text{F}} = 272.7$ Hz), 121.7, 93.8, 69.2, 43.9, 23.6, 11.0; FT-IR (neat): 3391, 2970, 2939, 1609, 1584, 1551, 1469, 1415, 1372, 1279, 1229, 1180, 1134, 1034, 986, 844, 828 cm^{-1} ; HRMS (ESI-TOF): calcd for $[\text{C}_{20}\text{H}_{16}\text{Cl}_2\text{F}_6\text{N}_2\text{O} + \text{H}]^+$ 485.0617: found 485.0613.




1-Propyl-2,5-bis{4-(trifluoromethyl)phenyl}-4,5-dihydro-1*H*-imidazol-5-ol (2g)

Following the representative procedure, **2g** was obtained (35.5 mg, 0.0853 mmol, 85%) as a white solid from **1f** (35.7 mg, 0.100 mmol). Decomposition temperature: 154-156 °C. ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 7.87 (d, $J = 8.2$ Hz, 2H), 7.83 (d, $J = 8.2$ Hz, 2H), 7.78 (d, $J = 8.3$ Hz, 2H), 7.75 (d, $J = 8.3$ Hz, 2H), 6.85 (brs, 1H), 3.97 (d, $J = 16.3$ Hz, 1H), 3.90 (d, $J = 16.3$ Hz, 1H), 3.13-3.09 (m, 1H), 2.75-2.68 (m, 1H), 1.26-1.17 (m, 1H), 0.97-0.90 (m, 1H), 0.48 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (125 MHz, $\text{CDCl}_3/\text{CD}_3\text{OD}$ (25 : 1)) δ 164.0, 146.8, 135.1, 132.0 (q, $J_{\text{C}-\text{F}} = 32.8$ Hz), 130.1 (q, $J_{\text{C}-\text{F}} = 33.0$ Hz), 128.4, 127.3, 125.5 (q, $J_{\text{C}-\text{F}} = 3.7$ Hz), 125.1 (q, $J_{\text{C}-\text{F}} = 3.6$ Hz), 124.0 (q, $J_{\text{C}-\text{F}} = 272.3$ Hz), 123.6 (q, $J_{\text{C}-\text{F}} = 272.2$ Hz), 94.4, 69.5, 44.2, 23.9, 11.2; FT-IR (neat): 3071, 2969, 2928, 1598, 1541, 1457, 1326, 1236, 1167, 1127, 1068, 1018, 965, 846 cm^{-1} ; HRMS (ESI-TOF): calcd for $[\text{C}_{20}\text{H}_{18}\text{F}_6\text{N}_2\text{O} + \text{H}]^+$ 417.1396: found 417.1398.



2-(4-Chlorophenyl)-1-propyl-5-{4-(trifluoromethyl)phenyl}-4,5-dihydro-1*H*-imidazol-5-ol (2h)


Following the representative procedure, **2h** (22.4 mg, 0.0585 mmol, 59%) as a white solid from **1g** (32.3 mg, 0.100 mmol). Decomposition temperature: 152-154 °C. ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 7.76 (d, $J = 8.4$ Hz, 2H), 7.74 (d, $J = 8.4$ Hz, 2H), 7.62 (d, $J = 8.3$ Hz, 2H), 7.56 (d, $J = 8.3$ Hz, 2H), 6.80 (brs, 1H), 3.94 (d, $J = 16.2$ Hz, 1H), 3.80 (d, $J = 16.2$ Hz, 1H), 3.12-3.06 (m, 1H), 2.74-2.68 (m, 1H), 1.27-1.19 (m, 1H), 0.98-0.91 (m, 1H), 0.48 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (125 MHz, $\text{CDCl}_3/\text{CD}_3\text{OD}$ (25 : 1)) δ 164.4, 146.9, 136.1, 130.0 (q, $J_{\text{C}-\text{F}} = 32.5$ Hz), 129.8, 129.2, 128.8, 126.6, 125.0 (q, $J_{\text{C}-\text{F}} = 3.5$ Hz), 124.0 (q, $J_{\text{C}-\text{F}} = 271.7$ Hz), 94.4, 69.0, 44.2, 23.8, 11.2; FT-IR (neat): 2967, 2874, 1610, 1588, 1496, 1456, 1379, 1326, 1236, 1163, 1127, 1093, 1014, 968, 833 cm^{-1} ; HRMS (ESI-TOF): calcd for $[\text{C}_{19}\text{H}_{18}\text{ClF}_3\text{N}_2\text{O} + \text{H}]^+$ 383.1133: found 383.1129.



2-(4-Fluorophenyl)-1-propyl-5-{4-(trifluoromethyl)phenyl}-4,5-dihydro-1*H*-imidazol-5-ol (2i)


Following the representative procedure, **2i** was obtained (24.0 mg, 0.0655 mmol, 66%) as a white solid from **1h** (30.7 mg, 0.100 mmol). Decomposition temperature: 148-151 °C. ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 7.76 (d,

J = 8.7 Hz, 2H), 7.74 (d, *J* = 8.7 Hz, 2H), 7.65 (dd, *J* = 5.7, 8.7 Hz, 2H), 7.33 (dd, *J* = 8.9, 8.9 Hz, 2H), 6.76 (brs, 1H), 3.93 (d, *J* = 16.2 Hz, 1H), 3.80 (d, *J* = 16.2 Hz, 1H), 3.12-3.06 (m, 1H), 2.74-2.68 (m, 1H), 1.26-1.18 (m, 1H), 1.00-0.91 (m, 1H), 0.48 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃/CD₃OD (25 : 1)) δ 164.4, 163.6 (d, *J*_{C-F} = 250.5 Hz), 146.9, 130.0 (q, *J*_{C-F} = 32.1 Hz), 129.9 (d, *J*_{C-F} = 8.5 Hz), 127.5 (d, *J*_{C-F} = 3.6 Hz), 126.7, 125.0 (q, *J*_{C-F} = 3.5 Hz), 124.0 (q, *J*_{C-F} = 271.9 Hz), 115.7 (d, *J*_{C-F} = 21.8 Hz), 94.9, 69.0, 44.3, 23.9, 11.2; FT-IR (neat): 3393, 2968, 2800, 1608, 1573, 1515, 1456, 1402, 1327, 1240, 1159, 1128, 1066, 1011, 975, 923, 837 cm⁻¹; HRMS (ESI-TOF): calcd for [C₁₉H₁₈F₄N₂O +H]⁺ 367.1428: found 367.1423.




1-Butyl-2-(2-fluorophenyl)-5-{4-(trifluoromethyl)phenyl}-4,5-dihydro-1*H*-imidazol-5-ol (2j)

Following the representative procedure, **2j** was obtained (30.5 mg, 0.0802 mmol, 80%) as a white solid from **1i** (30.7 mg, 0.100 mmol). Decomposition temperature: 161-164 °C. ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.77 (d, *J* = 8.4 Hz, 1H), 7.73 (d, *J* = 8.4 Hz, 2H), 7.58-7.53 (m, 2H), 7.36-7.33 (m, 2H), 6.78 (brs, 1H), 3.98 (d, *J* = 16.2 Hz, 1H), 3.85 (d, *J* = 16.2 Hz, 1H), 2.98-2.92 (m, 1H), 2.68-2.62 (m, 1H), 1.14-1.09 (m, 1H), 0.96-0.90 (m, 1H), 0.88-0.82 (m, 2H), 0.46 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃/CD₃OD (20 : 1)) δ 160.8, 159.5 (d, *J*_{C-F} = 249.0 Hz), 146.9, 131.8 (d, *J*_{C-F} = 8.0 Hz), 130.3 (d, *J*_{C-F} = 2.7 Hz), 130.0 (q, *J*_{C-F} = 33.4 Hz), 126.6, 125.1 (q, *J*_{C-F} = 3.5 Hz), 124.4 (d, *J*_{C-F} = 3.4 Hz), 124.1 (q, *J*_{C-F} = 271.7 Hz), 119.7 (d, *J*_{C-F} = 15.7 Hz), 115.8 (d, *J*_{C-F} = 21.1 Hz), 94.4, 69.6, 42.1, 32.6, 19.8, 13.1; FT-IR (neat): 3420, 2961, 2873, 1628, 1595, 1497, 1458, 1373, 1326, 1298, 1227, 1166, 1068, 1014, 970, 843 cm⁻¹; HRMS (ESI-TOF): calcd for [C₁₉H₁₈F₄N₂O +H]⁺ 367.1428: found 367.1433.




2-{4-fluoro-3-(trifluoromethyl)phenyl}-1-propyl-5-{4-(trifluoromethyl)phenyl}-4,5-dihydro-1*H*-imidazol-5-ol (2k)

Following the representative procedure, **2k** was obtained (41.3 mg, 0.0951 mmol, 91%) as a white solid from **1j** (39.2 mg, 0.104 mmol). Decomposition temperature: 138-140 °C. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.00-7.96 (m, 2H), 7.81 (d, *J* = 8.2 Hz, 1H), 7.74 (d, *J* = 8.4 Hz, 2H), 7.69-7.65 (m, 1H), 6.80 (brs, 1H), 3.95 (d, *J* = 16.3 Hz, 1H), 3.83 (d, *J* = 16.3 Hz, 1H), 3.13-3.06 (m, 1H), 2.74-2.68 (m, 1H), 1.25-1.18 (m, 1H), 0.99-0.91 (m, 1H), 0.50 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃/CD₃OD (25 : 1)) δ 162.9, 160.5 (d, *J*_{C-F} = 261.1 Hz), 146.5, 133.7 (d, *J*_{C-F} = 7.8 Hz), 130.2 (q, *J*_{C-F} = 33.2 Hz), 128.0, 127.2 (d, *J*_{C-F} = 4.2 Hz), 126.7, 125.1 (q, *J*_{C-F} = 3.6 Hz), 124.4 (q, *J*_{C-F} = 272.2 Hz), 124.2 (q, *J*_{C-F} = 272.6 Hz), 118.8 (dq, *J*_{C-F} = 12.9, 33.5 Hz), 117.4 (d, *J*_{C-F} = 21.1 Hz), 94.5, 69.5, 44.3, 24.0, 11.2; FT-IR (neat): 2973, 2876, 1612, 1582, 1510, 1460, 1326, 1285, 1166, 1128, 1068, 1014, 973, 899, 832 cm⁻¹; HRMS (ESI-TOF): calcd for [C₂₀H₁₇F₇N₂O +H]⁺ 435.1302: found




2-(4-fluoro-3-methoxyphenyl)-1-propyl-5-{4-(trifluoromethyl)phenyl}-4,5-dihydro-1H-imidazol-5-ol (2l)

Following the representative procedure, **2l** was obtained (22.4 mg, 0.0558 mmol, 56%) as a white solid from **1k** (33.7 mg, 0.100 mol). Decomposition temperature: 166-168 °C. ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.79-7.74 (m, 4H), 7.36-7.32 (m, 2H), 7.18 (brs, 1H), 6.78 (brs, 1H), 3.93 (d, *J* = 16.2 Hz, 1H), 3.89 (s, 3H), 3.81 (d, *J* = 16.2 Hz, 1H), 3.14-3.08 (m, 1H), 2.77-2.71 (m, 1H), 1.23 (m, 1H), 0.96 (m, 1H), 0.51 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃/CD₃OD (20 : 1)) δ 164.5, 153.2 (d, *J*_{C-F} = 250.0 Hz), 147.7 (d, *J*_{C-F} = 10.9 Hz), 146.8, 130.0 (q, *J*_{C-F} = 32.3 Hz), 127.7 (d, *J*_{C-F} = 3.6 Hz), 126.6, 125.0 (q, *J*_{C-F} = 3.5 Hz), 124.0 (q, *J*_{C-F} = 271.8 Hz), 120.4 (d, *J*_{C-F} = 7.3 Hz), 116.0 (d, *J*_{C-F} = 18.9 Hz), 113.4, 94.9, 68.8, 56.2, 44.2, 23.9, 11.2; FT-IR (neat): 3083, 2962, 2932, 1608, 1569, 1519, 1473, 1427, 1325, 1278, 1238, 1181, 1154, 1066, 1013, 980, 849 cm⁻¹; HRMS (ESI-TOF): calcd for [C₂₀H₂₀F₄N₂O₂ + H]⁺ 397.1534: found 397.1528.



2-(4-Fluoro-2-methylphenyl)-1-propyl-5-{4-(trifluoromethyl)phenyl}-4,5-dihydro-1H-imidazol-5-ol (2m)


Following the representative procedure, **2m** (22.8 mg, 0.0599 mmol, 60%) as a white solid from **1l** (32.1 mg, 0.100 mmol). Decomposition temperature: 106-109 °C. ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.76 (brs, 4H), 7.41 (dd, *J* = 6.4, 8.2 Hz, 1H), 7.19-7.17 (m, 1H), 7.15-7.12 (m, 1H), 6.74 (brs, 1H), 3.96 (d, *J* = 16.0 Hz, 1H), 3.87 (d, *J* = 16.0 Hz, 1H), 2.83-2.77 (m, 1H), 2.57-2.50 (m, 1H), 2.37 (s, 3H), 1.09-1.01 (m, 1H), 0.95-0.87 (m, 1H), 0.39 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 163.7, 163.0 (d, *J*_{C-F} = 248.9 Hz), 147.5, 139.2 (d, *J*_{C-F} = 8.2 Hz), 130.0 (d, *J*_{C-F} = 8.5 Hz), 127.3, 126.7, 124.9 (q, *J*_{C-F} = 2.3 Hz), 124.1 (q, *J*_{C-F} = 272.2 Hz), 123.1, 117.1 (d, *J*_{C-F} = 21.4 Hz), 112.6 (d, *J*_{C-F} = 21.6 Hz), 93.7, 69.6, 43.9, 23.6, 19.5, 11.3; FT-IR (neat): 2968, 2934, 2873, 1620, 1587, 1455, 1408, 1381, 1327, 1297, 1242, 1165, 1097, 1033, 971, 947, 837 cm⁻¹; HRMS (ESI-TOF): calcd for [C₂₀H₂₀F₄N₂O + H]⁺ 381.1585: found 381.1589.



1-(Cyclopropylmethyl)-2,5-bis{4-(trifluoromethyl)phenyl}-4,5-dihydro-1H-imidazol-5-ol (2n)


Following the representative procedure, **2n** (31.2 mg, 0.0728 mmol, 73%) as a white solid from **1f** (35.7 mg, 0.100 mmol). Decomposition temperature: 146-149 °C. ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.83 (d, *J* = 8.3 Hz, 2H), 7.84-7.80 (m, 4H), 7.74 (d, *J* = 8.3 Hz, 2H), 6.87 (brs, 1H), 4.00 (d, *J* = 16.3 Hz, 1H), 3.86 (d, *J* = 16.3 Hz, 1H), 2.84 (d, *J* = 6.6 Hz, 2H), 0.59-0.51 (m, 1H), 0.10-0.04 (m, 1H), -0.11--0.16 (m, 1H), -0.25--0.29 (m, 1H),

-0.65--0.70 (m, 1H); ^{13}C NMR (125 MHz, $\text{CDCl}_3/\text{CD}_3\text{OD}$ (25 : 1)) δ 164.2, 147.2, 135.2, 131.9 (q, $J_{\text{C}-\text{F}} = 32.7$ Hz), 129.8 (q, $J_{\text{C}-\text{F}} = 32.2$ Hz), 128.5, 126.8, 125.4 (q, $J_{\text{C}-\text{F}} = 3.5$ Hz), 124.8 (q, $J_{\text{C}-\text{F}} = 3.5$ Hz), 124.0 (q, $J_{\text{C}-\text{F}} = 271.9$ Hz), 123.6 (q, $J_{\text{C}-\text{F}} = 272.4$ Hz), 94.0, 69.5, 46.8, 11.4, 5.1, 3.8; FT-IR (neat): 3083, 2933, 2858, 1595, 1520, 1456, 1411, 1325, 1234, 1164, 1126, 1067, 1018, 969, 847 cm^{-1} ; HRMS (ESI-TOF): calcd for $[\text{C}_{21}\text{H}_{18}\text{F}_6\text{N}_2\text{O} + \text{H}]^+$ 429.1396: found 429.1390.




1-Isopentyl-2,5-bis{4-(trifluoromethyl)phenyl}-4,5-dihydro-1H-imidazol-5-ol (2o)

Following the representative procedure, **2o** (35.8 mg, 0.0806 mmol, 81%) as a colorless oil from **1f** (35.7 mg, 0.100 mmol). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 7.87 (d, $J = 8.2$ Hz, 2H), 7.82 (d, $J = 8.3$ Hz, 2H), 7.79 (d, $J = 8.3$ Hz, 2H), 7.75 (d, $J = 8.3$ Hz, 2H), 6.83 (brs, 1H), 3.98 (d, $J = 16.3$ Hz, 1H), 3.87 (d, $J = 16.4$ Hz, 1H), 3.16-3.10 (m, 1H), 2.80-2.73 (m, 1H), 1.20-1.09 (m, 2H), 0.79-0.73 (m, 1H), 0.47 (d, $J = 6.1$, 3H), 0.46 (d, $J = 6.1$, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 163.6, 147.1, 134.8, 132.1 (q, $J_{\text{C}-\text{F}} = 32.8$ Hz), 130.2 (q, $J_{\text{C}-\text{F}} = 32.2$ Hz), 128.6, 126.8, 125.4 (q, $J_{\text{C}-\text{F}} = 3.5$ Hz), 125.1 (q, $J_{\text{C}-\text{F}} = 3.4$ Hz), 124.0 (q, $J_{\text{C}-\text{F}} = 272.3$ Hz), 123.6 (q, $J_{\text{C}-\text{F}} = 272.2$ Hz), 94.3, 69.4, 40.8, 39.5, 25.9, 21.9; FT-IR (neat): 2961, 2932, 2873, 1622, 1600, 1521, 1469, 1412, 1370, 1326, 1235, 1168, 1069, 1018, 966, 847 cm^{-1} ; HRMS (ESI-TOF): calcd for $[\text{C}_{22}\text{H}_{22}\text{F}_6\text{N}_2\text{O} + \text{H}]^+$ 445.1709: found 445.1706.




1-Allyl-2,5-bis{4-(trifluoromethyl)phenyl}-4,5-dihydro-1H-imidazol-5-ol (2p)

Following the representative procedure, **2p** (27.2 mg, 0.0656 mmol, 66%) as a white solid from **1f** (35.7 mg, 0.100 mmol). Decomposition temperature: 125-127 °C. ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 7.83 (brs, 4H), 7.82 (d, $J = 8.3$ Hz, 2H), 7.74 (d, $J = 8.3$ Hz, 2H), 6.89 (brs, 1H), 5.55-5.47 (m, 1H), 4.69 (d, $J = 10.3$ Hz, 1H), 4.64 (d, $J = 17.3$ Hz), 4.01 (d, $J = 16.4$ Hz, 1H), 3.90 (d, $J = 16.4$ Hz, 1H), 3.78 (dd, $J = 6.7, 17.1$ Hz, 1H), 3.47 (dd, $J = 6.7, 17.1$ Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 163.6, 146.4, 135.3, 134.4, 132.3 (q, $J_{\text{C}-\text{F}} = 32.8$ Hz), 130.4 (q, $J_{\text{C}-\text{F}} = 34.7$ Hz), 128.8, 126.9, 125.4 (q, $J_{\text{C}-\text{F}} = 3.4$ Hz), 125.2 (q, $J_{\text{C}-\text{F}} = 3.1$ Hz), 124.0 (q, $J_{\text{C}-\text{F}} = 272.2$ Hz), 123.6 (q, $J_{\text{C}-\text{F}} = 272.5$ Hz), 116.9, 94.7, 69.2, 45.2; FT-IR (neat): 3081, 2939, 2860, 1620, 1560, 1541, 1455, 14121, 1326, 1298, 1235, 1167, 1068, 1018, 969, 846 cm^{-1} ; HRMS (ESI-TOF): calcd for $[\text{C}_{20}\text{H}_{16}\text{F}_6\text{N}_2\text{O} + \text{H}]^+$ 415.1240: found 415.1237.




1-(2-Ethoxyethyl)-2,5-bis{4-(trifluoromethyl)phenyl}-4,5-dihydro-1H-imidazol-5-ol (2q)

Following the representative procedure, **2q** (37.3 mg, 0.0836 mmol, 84%) as amorphous solid from **1f** (35.7 mg, 0.100 mmol). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.91 (d, *J* = 8.1 Hz, 2H), 7.86 (d, *J* = 8.1 Hz, 2H), 7.79 (d, *J* = 8.3 Hz, 2H), 7.75 (d, *J* = 8.3 Hz, 2H), 6.89 (brs, 1H), 4.00 (d, *J* = 16.4 Hz, 1H), 3.87 (d, *J* = 16.4 Hz, 1H), 3.33-3.29 (m, 1H), 3.11-3.05 (m, 1H), 3.02-2.94 (m, 4H), 0.91 (t, *J* = 7.0, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 162.5, 147.6, 135.1, 132.0 (*q*, *J*_{C-F} = 32.7 Hz), 130.1 (*q*, *J*_{C-F} = 32.0 Hz), 128.8, 126.6, 125.6 (*q*, *J*_{C-F} = 3.8 Hz), 125.3 (*q*, *J*_{C-F} = 3.6 Hz), 124.0 (*q*, *J*_{C-F} = 272.0 Hz), 123.7 (*q*, *J*_{C-F} = 272.5 Hz), 93.8, 71.1, 69.1, 66.8, 42.4, 14.6; FT-IR (neat): 3066, 2934, 2867, 1620, 1571, 1522, 1411, 1353, 1237, 1163, 1071, 1019, 982, 845 cm⁻¹; HRMS (ESI-TOF): calcd for [C₂₁H₂₀F₆N₂O +H]⁺ 447.1502: found 447.1504.




1-Butyl-2-(4-chlorophenyl)-4-methoxy-5-phenyl-4,5-dihydro-1H-imidazol-5-ol (2t)

Following the representative procedure, purification by PTLC (hexane : ethyl acetate = 50 : 50) afforded **2t** (13.9 mg, 0.0388 mmol, 39%) as a colorless oil from **1m** (28.6 mg, 0.100 mmol). ¹H NMR (400 MHz, CDCl₃) δ 7.59 (d, *J* = 7.8 Hz, 2H), 7.54 (d, *J* = 7.5 Hz, 2H), 7.44-7.31 (m, 5H), 4.93 (s, 1H), 4.55 (brs, 1H), 3.59 (s, 3H), 3.22-3.14 (m, 1H), 2.97-2.90 (m, 1H), 1.38-1.27 (m, 1H), 1.18-1.08 (m, 1H), 1.00 (sext, *J* = 7.2 Hz, 2H), 0.64 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 166.5, 143.3, 136.4, 129.9, 129.5, 128.8, 128.5, 128.1, 125.5, 101.8, 93.0, 57.6, 42.8, 32.4, 20.0, 13.5; HRMS (ESI-TOF): calcd for [C₂₀H₂₃ClN₂O₂ +H]⁺ 359.1521: found 359.1517.




2-(4-Chlorophenyl)-4-methoxy-1-propyl-4,5-dihydro-1H-imidazol-5-ol (2u)

Following the representative procedure, purification by PTLC (hexane : ethyl acetate = 50 : 50) afforded **2u** was obtained (27.4 mg, 0.102 mmol, 52%) as a colorless oil from **1n** (40.9 mg, 0.195 mmol). ¹H NMR (400 MHz, CDCl₃) For a major isomer: δ 7.50-7.39 (m, 4H), 4.92 (d, *J* = 1.9 Hz, 1H), 4.77 (d, *J* = 1.9 Hz, 1H), 3.50 (s, 3H), 3.24-3.20 (m, 1H), 3.11-3.03 (m, 2H), 1.56-1.48 (m, 2H), 0.77 (t, *J* = 7.4 Hz, 3H); For a minor isomer: δ 7.50-7.39 (m, 4H), 5.19 (d, *J* = 6.7 Hz, 1H), 5.09 (d, *J* = 6.7 Hz, 1H), 3.64 (s, 3H), 3.24-3.20 (m, 1H), 3.11-3.03 (m, 2H), 1.58-1.47 (m, 2H), 0.82 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 166.6, 166.1, 137.1, 136.4, 130.1, 129.6, 129.3, 128.9, 128.8, 128.2, 101.2, 93.8, 90.7, 84.0, 57.3, 55.6, 46.7, 45.7, 22.3, 22.0, 11.2, 11.1; FT-IR (neat): 3265, 2963, 2930, 1647, 1606, 1579, 1557, 1457, 1245, 1092, 1014, 978, 837 cm⁻¹; HRMS (ESI-TOF): calcd for [C₁₃H₁₇ClN₂O₂ +Na]⁺ 291.0871: found 291.0865.



4-((6-azidohexyl)oxy)-2-(4-chlorophenyl)-1-propyl-4,5-dihydro-1*H*-imidazol-5-ol (2v**)**


Following the representative procedure, **2v** was obtained (19.6 mg, 0.0516 mmol, 52%) as a colorless oil from **1o** (32.1 mg, 0.100 mmol). ¹H NMR (400 MHz, CDCl₃) For a major isomer: δ 7.48-7.38 (m, 4H), 4.88 (s, 1H), 4.79 (s, 1H), 3.80 (dt, *J* = 9.0, 6.6 Hz, 1H), 3.52 (dt, *J* = 9.1, 6.6 Hz, 1H), 3.27-3.17 (m, 3H), 3.10-3.01 (m, 1H), 1.68-1.40 (m, 10H), 0.76 (t, *J* = 7.4 Hz, 3H); For a minor isomer: δ 7.48-7.38 (m, 4H), 3.95 (dt, *J* = 9.0, 6.5 Hz, 1H), 3.66 (dt, *J* = 9.0, 6.5 Hz, 1H), 3.27-3.17 (m, 3H), 3.10-3.01 (m, 1H), 1.68-1.40 (m, 10H), 0.80 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 166.4, 166.0, 136.7, 136.3, 130.1, 129.6, 129.3, 128.8, 128.8, 128.7, 100.7, 92.6, 91.0, 83.9, 69.8, 67.8, 51.4, 51.3, 46.8, 45.7, 29.6, 29.5, 28.8, 28.7, 26.5, 25.7, 25.6, 22.4, 22.0, 11.2, 11.1; FT-IR (neat): 3327, 2934, 2863, 1606, 1582, 1557, 1498, 1457, 1346, 1315, 1243, 1176, 1092, 1015, 957, 836 cm⁻¹; HRMS (ESI-TOF): calcd for [C₁₈H₂₆ClN₅O₂ + H]⁺ 380.1848: found 380.1843.



4. Dehydration of 5-hydroxyimidazolines

2-(3,4-Dichlorophenyl)-1-propyl-5-(4-(trifluoromethyl)phenyl)-1*H*-imidazole (3a**)**


To a stirred solution of 2-(3,4-dichlorophenyl)-1-propyl-5-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-imidazol-5-ol (**2a**) (20.0 mg, 0.0479 mmol, 1.0 equiv.) in CH₂Cl₂ (0.50 mL), 2.6-lutidine (26.3 μL, 0.240 mmol, 5.0 equiv.) and trifluoroacetic anhydride (10.0 μL, 0.0719 mmol, 1.5 equiv.) were added at 0 °C under an argon atmosphere. After being stirred at the same temperature for 30 min, the reaction mixture was diluted with ethyl acetate and poured into water. The aqueous layer was extracted with two portions of ethyl acetate. The combined extract was washed with brine, dried over MgSO₄ and concentrated *in vacuo*. The residue was purified by PTLC (hexane : ethyl acetate = 90 : 10) to give 2-(3,4-dichlorophenyl)-1-propyl-5-(4-(trifluoromethyl)phenyl)-1*H*-imidazole (15.2 mg, 0.0381 mmol, 79%). Colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.77 (d, *J* = 1.8 Hz, 1H), 7.73 (d, *J* = 8.1 Hz, 2H), 7.58-7.55 (m, 3H), 7.49 (dd, *J* = 1.8, 8.3 Hz, 1H), 7.21 (s, 1H), 4.07 (t, *J* = 7.4, 2H), 1.35 (sext, *J* = 7.4 Hz, 2H), 0.57 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 147.7, 134.0, 133.8, 133.3, 133.1, 131.1, 130.8, 130.7, 130.4 (q, *J*_{C-F} = 32.5 Hz), 129.4, 128.9, 127.9, 125.9 (q, *J*_{C-F} = 3.9 Hz), 124.0 (q, *J*_{C-F} = 272.3 Hz), 47.0, 23.8, 10.6; FT-IR (neat): 2939, 1619, 1481, 1423, 1344, 1325, 1167, 1126, 1069, 1015, 943, 890, 849 cm⁻¹; HRMS (ESI-TOF): calcd for [C₁₉H₁₅Cl₂F₃N₂ + H]⁺ 399.0637: found 399.0641.



1-Butyl-2-(4-chlorophenyl)-4-methoxy-5-phenyl-1*H*-imidazole (3b**)**


To a stirred solution of 1-butyl-2-(4-chlorophenyl)-4-methoxy-5-phenyl-4,5-dihydro-1*H*-imidazol-5-ol (**2t**) (10.5 mg, 0.0293 mmol, 1.0 equiv.) in CH₂Cl₂ (0.50 mL), 2.6-lutidine (17.0 μL, 0.146 mmol, 5.0 equiv.) and

trifluoroacetic anhydride (8.25 μ L, 0.0585 mmol, 2.0 equiv.) were added at 0 °C under an argon atmosphere. After being stirred at the same temperature for 30 min, the reaction mixture was diluted with ethyl acetate and poured into water. The aqueous layer was extracted with two portions of ethyl acetate. The combined extract was washed with brine, dried over MgSO₄ and concentrated *in vacuo*. The residue was purified by PTLC (hexane : ethyl acetate = 80 : 20) to give 1-butyl-2-(4-chlorophenyl)-4-methoxy-5-phenyl-1*H*-imidazole (**3b**) (8.4 mg, 0.0246 mmol, 84%). Colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.56 (d, *J* = 8.3 Hz, 2H), 7.44-7.43 (m, 6H), 7.33-7.29 (m, 1H), 4.03 (t, *J* = 7.3 Hz, 2H), 3.95 (s, 3H), 1.31-1.24 (m, 2H), 0.93 (sext, *J* = 7.4, 2H), 0.61 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 153.2, 141.5, 134.5, 130.3, 129.8, 129.0, 128.9, 128.7, 127.1, 113.1, 56.7, 45.3, 32.2, 19.3, 13.3; FT-IR (neat): 2959, 2930, 1604, 1583, 1519, 1482, 1443, 1329, 1094, 1013, 836 cm⁻¹; HRMS (ESI-TOF): calcd for [C₂₀H₂₁ClN₂O +H]⁺ 341.1415: found 341.1410.



1-{2-(4-Chlorophenyl)-4-methoxy-1-propyl-1*H*-imidazol-5-yl}-2,2,2-trifluoroethan-1-one (3c**)**

To a stirred solution of 2-(4-chlorophenyl)-4-methoxy-1-propyl-4,5-dihydro-1*H*-imidazol-5-ol (**2u**) (32.6 mg, 0.121 mmol, 1.0 equiv.) in CH₂Cl₂ (1.5 mL), 2.6-lutidine (70.6 μ L, 0.607 mmol, 5.0 equiv.) and trifluoroacetic anhydride (34.2 μ L, 0.243 mmol, 2.0 equiv.) were added at 0 °C under an argon atmosphere. After being stirred at the same temperature for 30 min, the reaction mixture was diluted with ethyl acetate and poured into water. The aqueous layer was extracted with two portions of ethyl acetate. The combined extract was washed with brine, dried over MgSO₄ and concentrated *in vacuo*. The residue was purified by PTLC (hexane : ethyl acetate = 80 : 20) to give 1-{2-(4-chlorophenyl)-4-methoxy-1-propyl-1*H*-imidazol-5-yl}-2,2,2-trifluoroethan-1-one (**3c**) (18.6 mg, 0.0536 mmol, 44%). Colorless oil. ¹H NMR (500 MHz, CDCl₃) δ 7.53 (d, *J* = 8.7 Hz, 2H), 7.50 (d, *J* = 8.7 Hz, 2H), 4.22-4.19 (m, 2H), 4.09 (s, 3H), 1.70 (sext, *J* = 7.5 Hz, 2H), 0.82 (t, *J* = 7.5 Hz, 3H); ¹³C NMR (125 MHz, CD₃Cl) δ 168.2 (q, *J*_{C-F} = 37.8 Hz), 163.6, 151.1, 136.9, 130.6, 129.3, 127.3, 116.6 (q, *J*_{C-F} = 288.4 Hz), 56.7, 49.0, 24.3, 10.8; ¹⁹F NMR (376 MHz, CDCl₃) δ -75.8; FT-IR (neat): 2932, 1658, 1600, 1538, 1484, 1443, 1344, 1235, 1156, 1094, 1015, 982, 946, 838 cm⁻¹; HRMS (ESI-TOF): calcd for [C₁₅H₁₄ClF₃N₂O₂ +Na]⁺ 369.0588: found 369.0587.




6. References

1. Wang, X. Z.; Jia, J.; Zhang, Y.; Xu, W. R.; Liu, W.; Shi, F. N.; Wang, J. W. *J. Chin. Chem. Soc.* **2007**, *54*, 643-652.
2. Morita, T.; Fuse, S.; Nakamura, H. *Angew. Chem. Int. Ed.* **2016**, *55*, 13580-13584.
3. Morita, T.; Fukuhara, S.; Fuse, S.; Nakamura, H. *Org. Lett.* **2018**, *20*, 433-436.


7. NMR Spectra

3-(3,4-Dichlorophenyl)-5-{4-(trifluoromethyl)phenyl}isoxazole (1a)

¹H NMR (500 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)




5-{2-Chloro-4-(trifluoromethyl)phenyl}-3-(3,4-dichlorophenyl)isoxazole (1b)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)




3-(3,4-Dichlorophenyl)-5-(3,4-difluorophenyl)isoxazole (1c)

¹H NMR (500 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)




S20

3-(3,4-Dichlorophenyl)-5-{4-fluoro-3-(trifluoromethyl)phenyl}isoxazole (1d)

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (125 MHz, CDCl_3)




5-{3,5-Bis(trifluoromethyl)phenyl}-3-(3,4-dichlorophenyl)isoxazole (1e)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)




3,5-Bis{4-(trifluoromethyl)phenyl}isoxazole (1f)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)




3-(4-Chlorophenyl)-5-{4-(trifluoromethyl)phenyl}isoxazole (1g)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)




3-(4-Fluorophenyl)-5-{4-(trifluoromethyl)phenyl}isoxazole (1h)

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (125 MHz, CDCl_3)




3-(2-Fluorophenyl)-5-{4-(trifluoromethyl)phenyl}isoxazole (1i)

¹H NMR (500 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)




3-{4-Chloro-3-(trifluoromethyl)phenyl}-5-{4-(trifluoromethyl)phenyl}isoxazole (1j)

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (125 MHz, CDCl_3)




3-(4-Fuoro-3-methoxyphenyl)-5-{4-(trifluoromethyl)phenyl}isoxazole (1k)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)




3-(4-Fluoro-2-methylphenyl)-5-{4-(trifluoromethyl)phenyl}isoxazole (1l)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)




3-(4-Chlorophenyl)-5-phenylisoxazol-4-ol

^1H NMR (400 MHz, CD₃OD)




^{13}C NMR (125 MHz, CD₃OD)




3-(4-Chlorophenyl)-4-methoxy-5-phenylisoxazole (1m)

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (125 MHz, CDCl_3)




3-(4-Chlorophenyl)-4-methoxyisoxazole (1n)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)




4-((6-Azidohexyl)oxy)-3-(4-chlorophenyl)isoxazole (1o)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)




2-(3,4-Dichlorophenyl)-1-propyl-5-{4-(trifluoromethyl)phenyl}-4,5-dihydro-1*H*-imidazol-5-ol (2a)

¹H NMR (500 MHz, DMSO-*d*₆)




¹³C NMR (125 MHz, CDCl₃/CD₃OD (20 : 1))




2-(3,4-Dichlorophenyl)-1-butyl-5-{4-(trifluoromethyl)phenyl}-4,5-dihydro-1*H*-imidazol-5-ol (2b)

¹H NMR (500 MHz, DMSO-*d*₆)




¹³C NMR (125 MHz, CDCl₃/CD₃OD (20 : 1))




**5-{2-Chloro-4-(trifluoromethyl)phenyl}-2-(3,4-dichlorophenyl)-1-propyl-4,5-dihydro-1*H*-imidazol-5-ol
(2c)**

¹H NMR (500 MHz, DMSO-*d*₆)




¹³C NMR (125 MHz, CD₃Cl)




2-(3,4-Dichlorophenyl)-5-(3,4-difluorophenyl)-1-propyl-4,5-dihydro-1*H*-imidazol-5-ol (2d)

¹H NMR (500 MHz, DMSO-*d*₆)




¹³C NMR (125 MHz, CDCl₃/CD₃OD (25 : 1))




**2-(3,4-Dichlorophenyl)-5-{4-fluoro-3-(trifluoromethyl)phenyl}-1-propyl-4,5-dihydro-1*H*-imidazol-5-ol
(2e)**

¹H NMR (500 MHz, DMSO-*d*₆)




¹³C NMR (125 MHz, CDCl₃/CD₃OD (20 : 1))




5-{3,5-bis(trifluoromethyl)phenyl}-2-(3,4-dichlorophenyl)-1-propyl-4,5-dihydro-1*H*-imidazol-5-ol (2f)

¹H NMR (500 MHz, DMSO-*d*₆)





¹³C NMR (125 MHz, CDCl₃/CD₃OD (20 : 1))




1-Propyl-2,5-bis{4-(trifluoromethyl)phenyl}-4,5-dihydro-1*H*-imidazol-5-ol (2g)

¹H NMR (500 MHz, DMSO-*d*₆)




2-(4-Chlorophenyl)-1-propyl-5-{4-(trifluoromethyl)phenyl}-4,5-dihydro-1*H*-imidazol-5-ol (2h)

¹H NMR (500 MHz, DMSO-*d*₆)





¹³C NMR (125 MHz, CDCl₃/CD₃OD (25 : 1))




2-(4-Fluorophenyl)-1-propyl-5-{4-(trifluoromethyl)phenyl}-4,5-dihydro-1*H*-imidazol-5-ol (2i)

¹H NMR (500 MHz, DMSO-*d*₆)




1-Butyl-2-(2-fluorophenyl)-5-{4-(trifluoromethyl)phenyl}-4,5-dihydro-1*H*-imidazol-5-ol (2j)

¹H NMR (500 MHz, DMSO-*d*₆)




¹³C NMR (125 MHz, CDCl₃/CD₃OD (20 : 1))




2-{4-fluoro-3-(trifluoromethyl)phenyl}-1-propyl-5-{4-(trifluoromethyl)phenyl}-4,5-dihydro-1*H*-imidazol-5-ol (2k)

¹H NMR (500 MHz, DMSO-*d*₆)




¹³C NMR (125 MHz, CDCl₃/CD₃OD (25 : 1))




2-(4-fluoro-3-methoxyphenyl)-1-propyl-5-{4-(trifluoromethyl)phenyl}-4,5-dihydro-1*H*-imidazol-5-ol (2l)

¹H NMR (500 MHz, DMSO-*d*₆)




¹³C NMR (125 MHz, CDCl₃/CD₃OD (20 : 1))




2-(4-Fluoro-2-methylphenyl)-1-propyl-5-{4-(trifluoromethyl)phenyl}-4,5-dihydro-1H-imidazol-5-ol (2m)

¹H NMR (500 MHz, DMSO-*d*₆)




¹³C NMR (125 MHz, CDCl₃)




1-(Cyclopropylmethyl)-2,5-bis{4-(trifluoromethyl)phenyl}-4,5-dihydro-1*H*-imidazol-5-ol (2n**)**

¹H NMR (500 MHz, DMSO-*d*₆)




¹³C NMR (125 MHz, CDCl₃/CD₃OD (25 : 1))




1-Isopentyl-2,5-bis{4-(trifluoromethyl)phenyl}-4,5-dihydro-1*H*-imidazol-5-ol (2o**)**

¹H NMR (500 MHz, DMSO-*d*₆)




¹³C NMR (125 MHz, CDCl₃)




1-Allyl-2,5-bis{4-(trifluoromethyl)phenyl}-4,5-dihydro-1*H*-imidazol-5-ol (2p)

¹H NMR (500 MHz, DMSO-*d*₆)




¹³C NMR (125 MHz, CDCl₃)




1-(2-Ethoxyethyl)-2,5-bis{4-(trifluoromethyl)phenyl}-4,5-dihydro-1*H*-imidazol-5-ol (2q)

¹H NMR (500 MHz, DMSO-*d*₆)




¹³C NMR (125 MHz, CDCl₃)




S50

1-Butyl-2-(4-chlorophenyl)-4-methoxy-5-phenyl-4,5-dihydro-1*H*-imidazol-5-ol (2t)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)




2-(4-Chlorophenyl)-4-methoxy-1-propyl-4,5-dihydro-1*H*-imidazol-5-ol (2u)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)




4-((6-azidohexyl)oxy)-2-(4-chlorophenyl)-1-propyl-4,5-dihydro-1*H*-imidazol-5-ol (2v)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)




2-(3,4-Dichlorophenyl)-1-propyl-5-(4-(trifluoromethyl)phenyl)-1*H*-imidazole (3a)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)




1-Butyl-2-(4-chlorophenyl)-4-methoxy-5-phenyl-1*H*-imidazole (3b)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)




1-{2-(4-Chlorophenyl)-4-methoxy-1-propyl-1*H*-imidazol-5-yl}-2,2,2-trifluoroethan-1-one (3c)

¹H NMR (500 MHz, CDCl₃)



¹³C NMR (125 MHz, CDCl₃)



¹⁹F NMR (376 MHz, CDCl₃)

